What is the recommended treatment regimen for inflammatory bowel disease, including induction and maintenance therapies for ulcerative colitis and Crohn's disease?

Inflammatory Bowel Disease Treatment

For moderate-to-severe Crohn's disease, start with anti-TNF therapy (infliximab or adalimumab) combined with a thiopurine in patients with poor prognostic factors; for moderate-to-severe ulcerative colitis, use infliximab or vedolizumab as first-line biologic therapy. 1, 2, 3

Treatment Algorithm for Crohn's Disease

Induction Therapy

Moderate-to-severe disease with poor prognostic factors:

• First-line: Anti-TNF therapy (infliximab or adalimumab) combined with thiopurine 1
• Poor prognostic factors include: young age at diagnosis, extensive disease, perianal involvement, deep ulcerations, or early need for corticosteroids
• Evaluate response between 8-12 weeks to determine need for therapy modification 1

Moderate-to-severe disease after conventional therapy failure:

• If corticosteroids, thiopurines, or methotrexate fail: use anti-TNF therapy (strong recommendation, high-quality evidence) 1
• After anti-TNF failure: use vedolizumab or ustekinumab (strong recommendation, moderate-quality evidence) 1
• After failure of corticosteroids, thiopurines, methotrexate, or anti-TNF: use risankizumab or upadacitinib 2

Positioning by prior exposure:

• Biologic-naïve patients: Anti-TNF therapy remains first choice
• Anti-TNF exposed with inadequate response: Risankizumab shows superiority over ustekinumab for endoscopic remission at 48 weeks 2
• Multiple therapy failures: Upadacitinib is the first oral agent effective for both induction and maintenance 2

Maintenance Therapy

After successful induction:

• Continue the same agent that achieved remission (strong recommendation, high-quality evidence) 1
• Never use corticosteroids for maintenance 2

For suboptimal response or loss of response:

• Dose intensification guided by therapeutic drug monitoring (conditional recommendation) 1
• Evaluate vedolizumab response at 10-14 weeks; ustekinumab response should be assessed similarly 1

Thiopurines and methotrexate:

• Do NOT use thiopurine monotherapy for induction 1
• May use for maintenance, but typically require another agent for induction
• Parenteral methotrexate can maintain remission but requires 12-16 weeks to assess efficacy 1

Treatment Algorithm for Ulcerative Colitis

Mild-to-Moderate Disease

Distal colitis (up to sigmoid-descending junction):

• Topical mesalazine 1g daily PLUS oral mesalazine 2-4g daily (grade A) 4
• Topical formulation depends on extent: suppositories for rectum, foam/liquid enemas for more proximal disease
• If combination fails: add oral prednisolone 40mg daily, taper over 8 weeks 4

Left-sided or extensive colitis:

• Oral aminosalicylates (mesalazine 2-4g daily) or corticosteroids 4
• Prednisolone 40mg daily for prompt response or after mesalazine failure 4
• Steroid-dependent disease: Add azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day 4

Beclomethasone dipropionate:

• 5mg daily for 4 weeks when 5-ASA fails and patient wishes to avoid systemic steroids (conditional recommendation, moderate certainty) 2
• High first-pass metabolism provides topical effect with lower systemic risk

Moderate-to-Severe Disease (Biologic-Naïve)

First-line biologic choice:

• Infliximab or vedolizumab preferred over adalimumab (conditional recommendation, moderate certainty) 3
• Network meta-analysis shows superior efficacy for infliximab and vedolizumab
• Adalimumab may be chosen by patients prioritizing self-administered subcutaneous injection convenience 3

Combination therapy:

• Combine TNF antagonists, vedolizumab, or ustekinumab with thiopurines or methotrexate rather than biologic monotherapy (conditional recommendation, low certainty) 3
• Patients with less severe disease who prioritize safety may choose monotherapy 3

Moderate-to-Severe Disease (Prior Biologic Exposure)

After infliximab failure (especially primary non-response):

• Use ustekinumab or tofacitinib rather than vedolizumab or adalimumab (conditional recommendation, low certainty) 3
• Ustekinumab: 15.6% clinical remission at week 8 with 130mg or 6mg/kg induction; 38.4-43.8% remission at week 44 with maintenance 2
• Vedolizumab shows trivial treatment effect in anti-TNF exposed patients 2

Newer agents:

• Risankizumab: 20.3% clinical remission at week 12 vs 6.2% placebo; maintenance data support continued use (conditional recommendation, moderate certainty) 2
• Upadacitinib: First oral agent for UC; currently recommended after anti-TNF failure 2

Acute Severe Ulcerative Colitis (Hospitalized Patients)

Initial management:

• Intravenous methylprednisolone 40-60mg daily (or equivalent) 3
• Exclude infectious etiologies but do NOT delay corticosteroid treatment 4
• Monitor: pulse rate, stool frequency, C-reactive protein, plain abdominal radiograph 4

Corticosteroid-refractory disease (after 3-5 days):

• Infliximab or cyclosporine for patients preferring medical management 3
• No clear evidence favoring intensive vs standard infliximab dosing (knowledge gap) 3
• Maintain close liaison with colorectal surgeon 4

Critical Implementation Points

Timing and Monitoring

Response assessment windows:

• Anti-TNF therapy: 8-12 weeks 1
• Vedolizumab: 10-14 weeks 1
• Thiopurines/methotrexate: 12-16 weeks 1
• Prednisolone taper: 8 weeks (more rapid reduction causes early relapse) 4

Treatment targets:

• Aim for complete remission (clinical AND endoscopic/histologic) 2
• Mucosal healing prevents complications, reduces surgery, hospitalizations, and steroid exposure 5

Common Pitfalls to Avoid

Do NOT:

• Use corticosteroids for maintenance therapy 2
• Use thiopurine monotherapy for induction in Crohn's disease 1
• Use methotrexate monotherapy for ulcerative colitis 3
• Continue 5-ASA in patients achieving remission with biologics/immunomodulators (conditional recommendation) 3
• Switch between anti-TNF therapies in patients doing well 1

Safety considerations:

• Upadacitinib: Black box warning for VTE and MACE in higher-risk patients; monitor for acne and VZV 2
• Therapeutic drug monitoring should guide dose optimization for anti-TNF loss of response 1

Early vs Step-Up Therapy

For high-risk disease:

• Use biologics with or without immunomodulators early rather than gradual step-up after 5-ASA failure (conditional recommendation, very low certainty) 3
• Patients with less severe disease who prioritize 5-ASA safety may choose gradual step-up 3

This algorithmic approach prioritizes rapid disease control, mucosal healing, and avoidance of corticosteroid-related complications while providing clear decision points based on disease severity, location, and prior treatment response.